ESC Guidelines: CRT Gets Nod For Mild Symptoms, But Not Asymptomatic HF
This article was originally published in The Gray Sheet
Executive Summary
New European 1guidelines provide strong support for extending cardiac resychronization therapy to a broader set of heart failure patients, but not quite the same population as an FDA panel recently recommended in the U.S
You may also be interested in...
Blues TEC Assessment Endorses CRT For Mild Heart Failure
Using cardiac resynchronization therapy to treat patients suffering from mild heart failure is supported by existing clinical evidence. That is not the case, however, for asymptomatic patients, according to a new assessment issued by Blue Cross Blue Shield’s Technology Evaluation Center.
Blues TEC Assessment Endorses CRT For Mild Heart Failure
Using cardiac resynchronization therapy to treat patients suffering from mild heart failure is supported by existing clinical evidence. That is not the case, however, for asymptomatic patients, according to a new assessment issued by Blue Cross Blue Shield’s Technology Evaluation Center.
Medtronic’s RAFT Keeps Hopes Afloat For Shift To CRT In Milder Heart Failure
Data reported last week could hasten moves by electrophysiologists to implant price-premium cardiac resynchronization therapy systems rather than conventional defibrillators in patients with earlier stage heart failure.